Declaration on 18 January 2014
Benefits received from pharmaceutical companies
- Company: Eisai Ltd · Reason for receipt of fees: Honorarium for chairing satellite symposium at ENS 2013 · Total amount received: £2,000 to under £5,000
- Company: UCB Pharma Ltd · Reason for receipt of fees: Speaker for for Epilepsy Masterclass 2013 · Total amount received: £1,000 to under £2,000
- Company: GSK · Reason for receipt of fees: Travel, registration & Accomodation fees to attend AES 2012 · Total amount received: £1,000 to under £2,000
- Company: Lupin Pharmaceuticals · Reason for receipt of fees: Travel expenses, accomodation & speaker honorarium for ENS-Indian Neurological Society teaching course 2012 · Total amount received: £2,000 to under £5,000
Other sources of income or benefits from other organisations relevant to medical practice
- Company: Transport for London, Occupational Health · Reason for receipt of fees: Neurology Advisor (Average Annual total for medical reports, advice) · Total amount received: £1,000 to under £2,000
Past declarations
Last 2 years (2012-13 covered above). Prior to that since 2009:
2010 GSK, COnsultancy honorarium
2010 Eisai, American Epilepsy Society meeting Registration fee, £276
2011 GSK, Amedican Epilepsy Society meeting, travel, accomodation & registration, £1500
2011 UCB Ltd, Travel & accomodation for Forum of Excellence, epilepsy educational meeting, £450
Other declarations
Other honoraria and speaker fees (for any work undertaken during employed hours) are paid to St Georges, University of London to support local epilepsy research and education.
Dr Cock also has a medicolegal practice specialising in epilepsy, work for which is undertaken in her own time and never in relation to patients under her care.
Various other roles including external research and publication referee activities, European Neurological Society Teaching Course Director and as Clinical Lead for ebrain are unpaid.